Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1, Randomized, Dose and Schedule Evaluation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Belantamab Mafodotin Administered in Combination With Standard of Care in Participants With Newly Diagnosed Multiple Myeloma
Eligible patients will receive the combination of bortezomib, lenalidomide and dexamethasone (VRd) on a 3-week cycle for 8-cycles. This will be followed by the combination of lenalidomide and dexamethasone (Rd) on a 4-week cycle thereafter, as per the dosing schedule. Belantamab mafodotin will be administered intravenously to patients according to their assigned cohort, of which there are seven.